Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

At a Technical University of Denmark lab, researchers are exploring the potential for fungi to be used as meat and seafood ...

Novo Nordisk ( NVO 0.15%) has found phenomenal success in treating patients with obesity and diabetes. *Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Novo Nordisk A/S has logged a -20.1% 52 week change, compared to 25.4% for the S&P 500 NVO has an average analyst rating of buy and is -26.9% away from its mean target price of $120.67 per share ...

Today, we keep an eye on final PMI data for the euro area, the US, Norway, Sweden, and the UK. The flash release came very early in December, so the final release could deviate more than usual, which ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.